Astrazeneca (AZN) Tax Provisions (2009 - 2026)

Astrazeneca (AZN) has reported Tax Provisions for 18 consecutive years, with $3.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Tax Provisions fell 23.43% year-over-year to $3.1 billion; the TTM figure through Mar 2026 stood at $12.0 billion (up 18.58% YoY), while the FY2025 annual figure was $2.2 billion, up 31.45% from the prior year.
• Tax Provisions came in at $3.1 billion for Q1 2026 at Astrazeneca, up from $2.8 billion in the prior quarter.
• The five-year high for Tax Provisions was $4.0 billion in Q1 2025, with the low at -$1.2 billion in Q2 2022.
• Average Tax Provisions over 5 years is $2.0 billion, with a median of $1.9 billion recorded in 2024.
• The largest YoY upside for Tax Provisions was 980.43% in 2022 against a maximum downside of 202.35% in 2022.
• Year by year, Tax Provisions stood at $1.7 billion in 2022, then climbed by 3.91% to $1.8 billion in 2023, then retreated by 15.73% to $1.5 billion in 2024, then surged by 85.27% to $2.8 billion in 2025, then advanced by 10.87% to $3.1 billion in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $3.1 billion, $2.8 billion, and $2.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.